Kalyra Pharmaceuticals, Inc. — Department of Defense SBIR Phase II: Non-DOD

Kalyra Pharmaceuticals, Inc. — SBIR Phase II award from Department of Defense.

Amount
$999,830
Agency
Department of Defense · Defense Health Program
Program / Phase
SBIR · Phase II
Topic
Non-DOD
Solicitation
2017.0
NAICS
Place of performance
CA
Period
2017-09-25 → 2019-02-24

Description

There has been considerable interest in the development of alternative therapies for pain management that are neither opioid nor non-steroidal anti-inflammatory drugs (NSAIDs). Kalyra Pharmaceuticals has demonstrated that acetaminophen, also known as APAP